Drug costs in the management of metastatic castration-resistant prostate cancer in Canada

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Dragomir, Alice ^a,b   Dinea, Daniela ^a,c   Vanhuyse, Marie ^a,b   Cury, Fabio L ^a,b   Aprikian, Armen G ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cost of drugs for metastatic castration resistant prostate cancer in Canada; Cost of treatments; Markov model; Metastatic castration resistant prostate cancer; Treatments for advanced prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

CANADA; COST; DISEASE MANAGEMENT; DRUG COST; ECONOMICS; HEALTH SERVICES RESEARCH; HUMAN; MALE; MORTALITY; PATHOLOGY; PROBABILITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CANADA; COSTS AND COST ANALYSIS; DISEASE MANAGEMENT; DRUG COSTS; HEALTH SERVICES RESEARCH; HUMANS; MALE; MARKOV CHAINS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

EID: 84902051556     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-252     Document Type: Article

References (56)

1. Canadian Cancer Statistics 2012. Statistics Canada, Toronto, ON: Canadian Cancer Society 2012
2. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Huggins C, Hodges CV, J Urol 2002 168 1 9 12 Epub 2002/06/07
3. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Huggins C, Hodges CV, CA Cancer J Clin 1972 22 4 232 240 Epub 1972/07/01
4. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. de Jong IJ, Eaton A, Bladou F, Curr Med Res Opin 2007 23 5 1077 1080 Epub 2007/05/24 (Pubitemid 46799591)
5. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. Labrie F, J Androl 2004 25 3 305 313 Epub 2004/04/06 (Pubitemid 38509224)
6. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Cook T, Sheridan WP, Oncologist 2000 5 2 162 168 Epub 2000/05/05 (Pubitemid 30238236)
7. Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist. Moul JW, Nat Rev Urol 2012 9 3 125 126 Epub 2012/02/01
8. LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy? Keizman D, Eisenberger MA, Oncology (Williston Park) 2009 23 7 631 632 Epub 2009/07/25
9. The role of LHRH antagonists in the treatment of prostate cancer. Crawford ED, Hou AH, Oncology (Williston Park) 2009 23 7 626 630 Epub 2009/07/25
10. Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84. Weston P, Persson BE, Eur Urol 2005 47 3 422 author reply. Epub 2005/02/18 (Pubitemid 40248875)
11. Androgen deprivation therapy: past, present and future. Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE, BJU Int 2012 109 Suppl 6 1 12 Epub 2012/06/15
12. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study 30853. Newling DW, Denis L, Vermeylen K, Cancer 1993 72 12 Suppl 3793 3798 Epub 1993/12/15 (Pubitemid 23361529)
13. Characterising the castration-resistant prostate cancer population: a systematic review. Kirby M, Hirst C, Crawford ED, Int J Clin Pract 2011 65 11 1180 1192 Epub 2011/10/15
14. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. Lee JL, Eun Kim J, Ahn JH, Lee DH, Lee J, Kim CS, Hyuk Hong J, Hong B, Song C, Ahn H, Am J Clin Oncol 2011 34 2 140 144 Epub 2010/08/06
15. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL, J Bone Miner Res 2012 Epub 2012/09/01
16. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y, Prostate Cancer Prostatic Dis 2007 10 2 194 201 Epub 2007/01/03 (Pubitemid 46881672)
17. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN, Urol Int 2005 75 3 217 221 Epub 2005/10/11 (Pubitemid 41433869)
18. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ, J Clin Oncol 2004 22 6 1025 1033 Epub 2004/03/17 (Pubitemid 41095034)
19. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Paul R, Breul J, Drug Saf 2000 23 5 381 390 Epub 2000/11/21
20. Abiraterone in metastatic prostate cancer without previous chemotherapy. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, et al. N Engl J Med 2013 368 2 138 148 Epub 2012/12/12
21. Bone loss associated with the use of LHRH agonists in prostate cancer. Peters JL, Fairney A, Kyd P, Patel A, Rogers S, Webster JJ, Vale JA, Witherow RO, Prostate Cancer Prostatic Dis 2001 4 3 161 166 Epub 2002/12/24 (Pubitemid 32923230)
22. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K, Eur J Cancer Care (Engl) 2010 19 6 755 760 Epub 2009/08/28
23. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C, Lancet 2011 377 9768 813 822 Epub 2011/03/01
24. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C, Lancet 2012 379 9810 39 46 Epub 2011/11/19
25. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Carter JA, Botteman MF, Expert Rev Pharmacoecon Outcomes Res 2012 12 4 425 437 Epub 2012/05/01
26. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, N Engl J Med 2004 351 15 1502 1512 Epub 2004/10/08 (Pubitemid 39315317)
27. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED, N Engl J Med 2004 351 15 1513 1520 Epub 2004/10/08 (Pubitemid 39315318)
28. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC, J Clin Oncol 1996 14 6 1756 1764 Epub 1996/06/01 (Pubitemid 26185452)
29. Guidelines for the management of castrate-resistant prostate cancer. Saad F, Hotte SJ, Can Urol Assoc J 2010 4 6 380 384 Epub 2010/12/31
30. CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, Fleshner N, Gleave M, Kapoor A, Kassouf W, Loblaw A, North S, Usmani N, Chi KN, Can Urol Assoc J 2013 7 7-8 231 237 Epub 2013/09/14
31. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P, BJU Int 2010 106 7 974 978 Epub 2010/03/17
32. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J, Oncol Rep 2008 20 4 891 896 Epub 2008/09/25
33. New developments in castrate-resistant prostate cancer. Shore N, Mason M, de Reijke TM, BJU Int 2012 109 Suppl 6 22 32 Epub 2012/06/15
34. Abiraterone and increased survival in metastatic prostate cancer. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, et al. N Engl J Med 2011 364 21 1995 2005 Epub 2011/05/27
35. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Oudard S, Future Oncol 2011 7 4 497 506 Epub 2011/04/06
36. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Lancet 2010 376 9747 1147 1154 Epub 2010/10/05
37. Increased survival with enzalutamide in prostate cancer after chemotherapy. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, N Engl J Med 2012 367 13 1187 1197 Epub 2012/08/17
38. MC-Cancer de la prostate, Avis de refus. Institut national d'excellence en santé et en services sociaux, Quebec, QC: Institut national d'excellence en santé et en services sociaux 2012
39. MC-Cancer de la prostate. PROJET PILOTE EN ONCOLOGIE: Avis de refus à défaut d'une entente de partage de risques financiers. Institut national d'excellence en santé et en services sociaux, Quebec, QC: Institut national d'excellence en santé et en services sociaux 2012
40. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Chodak GW, Mitchell P, Porter L, BJU Int 1999 83 7 801 806 Epub 1999/06/15 (Pubitemid 29224400)
41. Hunink MGM, Glasziou PP, Siegel JE, Weeks JC, Pliskin JS, Elstein AS, Weinstein MC, Decision Making in Health and Medicine: Interpreting Evidence and Values Cambridge: Cambridge University Press 2001
42. Liste de médicaments assurés. Régie de l'Assurance Maladie du Québec (RAMQ), Édition 34-1er février 2012 Québec,QC: Régie de l'Assurance Maladie du Québec 2012
43. Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J, Value Health 2012 15 6 821 827 Epub 2012/09/25
44. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation. Hollingworth W, Spackman DE, Acad Radiol 2007 14 4 406 410 Epub 2007/03/21 (Pubitemid 46401414)
45. Discrete event simulation: the preferred technique for health economic evaluations? Caro JJ, Moller J, Getsios D, Value Health 2010 13 8 1056 1060 Epub 2010/09/10
46. Pharmacy list. Montreal General Hospital, Montreal, QC: McGill University Health Center 2013
47. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R, Health Technol Assess 2007 11 2 ii iv xv-xviii, 1-179. Epub 2006/12/22
48. Healthcare costs associated with prostate cancer: estimates from a population-based study. Krahn MD, Zagorski B, Laporte A, Alibhai SM, Bremner KE, Tomlinson G, Warde P, Naglie G, BJU Int 2010 105 3 338 346 Epub 2009/07/15
49. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L, CMAJ 2000 162 7 987 992 Epub 2000/04/14 (Pubitemid 30207497)
50. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. Alemayehu B, Buysman E, Parry D, Becker L, Nathan F, J Med Econ 2010 13 2 351 361 Epub 2010/05/25
51. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. Mehra M, Wu Y, Dhawan R, J Med Econ 2012 15 5 836 843 Epub 2012/04/03
52. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Crawford ED, Flaig TW, Oncology (Williston Park) 2012 26 1 70 77 Epub 2012/03/08
53. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, Asahi S, Furuya S, Tasaka A, Bioorg Med Chem 2011 19 21 6383 6399 Epub 2011/10/08
54. Alpha emitter radium-223 and survival in metastatic prostate cancer. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, N Engl J Med 2013 369 3 213 223 Epub 2013/07/19
55. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, N Engl J Med 2010 363 5 411 422 Epub 2010/09/08
56. Angiogenesis inhibition in prostate cancer: current uses and future promises. Aragon-Ching JB, Madan RA, Dahut WL, J Oncol 2010 2010 361836 Epub 2010/02/20